Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria.
Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria.
Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria. As a chronic disease it requires constant management.
It affects nearly 20 - 50% of the global population and is associated with a range of co-morbitities like diabetes or Alzheimer’s disease.
It affects nearly 20 - 50% of the global population and is associated with a range of co-morbitities like diabetes or Alzheimer’s disease.
It affects nearly 20 - 50% of the global population and is associated with a range of co-morbitities like diabetes or Alzheimer’s disease.
Current treatments involve painful removal of the whole biofilm followed by daily disinfection or antibiotics that keep disrupting the natural biofilm. Therefore patients loose biofilm homeostasis incl. beneficial bacteria with its metabolic and immunologic support and are more prone to recurrent infections.
Current treatments involve painful removal of the whole biofilm followed by daily disinfection or antibiotics that keep disrupting the natural biofilm. Therefore patients loose biofilm homeostasis incl. beneficial bacteria with its metabolic and immunologic support and are more prone to recurrent infections.
Current treatments involve painful bacteria removal and daily disinfection, disrupting microbiome balance and impairing beneficial bacteria's metabolic and immunologic functions.
PerioTrap possesses many years of experience in drug development. The company’s team combines competences in the field of medicinal chemistry, compound characterization, microbiology, clinical and product development.
The collective track record includes the successful development of several drug development projects in the area of small molecules. This includes the development of DP4 inhibitors as antidiabetics and the development of a novel pharmacological approach for the treatment of Alzheimer's disease (currently in phase IIb).
Honorary Professor of Proteinbiotechnolgy, Department of Biotechnology, Anhalt University of Applied Science, Köthen, Germany
School of Dental Medicine, University of Bern
Head of Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland and Distinguish University Scholar, Department of Oral Immunity and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY, USA.
Clinic for Cariology, Endodontology and Periodontology, University Hospital of Leipzig.
IBD Consulting & Co.
Pharmaceutical Technology, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle, Germany